Evidence map›Paper›PMID 41240289›Full record

SynthesisInternational journal of hematology2026

Chronic myeloid leukemia with atypical transcript e8a2: a case report and literature review.

Xikun Liu, Jirui Zhong, Man Luo, Xuekui Gu, Jiduo Liu, Zenghui Liu, Jing He, Yaohe Li

Abstract readCase ReportsSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xikun Liu *The First Clinical Medical School of Guangzhou University of Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.
Jirui Zhong *The First Clinical Medical School of Guangzhou University of Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.
Man LuoDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China. biry2022@163.com.
Xuekui GuDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China. guxuekui1067@163.com.
Jiduo LiuDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.
Zenghui LiuDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.
Jing HeDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.
Yaohe LiDepartment of Hematology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, No.16 Jichang Road, Guangzhou, 510405, Guangdong Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is characterized by the BCR::ABL1 fusion gene, resulting from Philadelphia (Ph) chromosome rearrangements that generate abnormal t (9; 22)(q34;q11) translocations. The most common fusion variants are e13a2 and e14a2. We diagnosed a case of CML with the rare e8a2 fusion variant using real-time quantitative PCR and sequencing. Although the e8a2 variant is increasingly reported in CML, comprehensive retrospective analyses remain scarce. Through a systematic review of published e8a2 BCR::ABL1 cases, we summarized the classification, treatment outcomes, and prognostic characteristics associated with this rare genotype. This analysis aims to provide additional evidence to facilitate improved diagnosis and therapeutic strategies for e8a2-positive CML patients.

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFemaleHumansMaleMiddle AgedTranslocation, GeneticFusion Proteins, bcr-ablBCR::ABL1Chronic myeloid leukemiaE8a2PhiladelphiaTyrosine kinase inhibitors

Identifiers

PMID41240289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.